卡罗维林(Caroverine) - 药物靶点：AMPA receptor x NMDA receptor_在研适应症：疼痛，痉挛_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Caroverine (INN)、Spasmium、Tinnex

靶点

AMPA receptor x NMDA receptor

作用方式

拮抗剂

作用机制

AMPA receptor拮抗剂(离子型谷氨酸受体AMPA拮抗剂)、NMDA receptor拮抗剂(谷氨酸[NMDA]受体复合体拮抗剂)

治疗领域

神经系统疾病

在研适应症

疼痛痉挛

非在研适应症

内耳疾病耳鸣

原研机构-

在研机构-

非在研机构

Phafag AG

权益机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H27N3O2

InChIKeyMSPRUJDUTKRMLM-UHFFFAOYSA-N

CAS号23465-76-1

关联

3

项与卡罗维林相关的临床试验

CTRI/2024/06/068528

/ Not yet recruiting临床2/3期

EFFICACY AND SAFETY OF CAROVERINE VERSUS AMITRIPTYLINE IN TREATMENT OF TINNITUS. - nil

开始日期2024-06-15

申办/合作机构-

CTRI/2023/12/060445

/ Not yet recruitingN/A

Effect of Bhramari Pranayama over oral Caroverine and counseling in the management of Tinnitus: A Randomized Controlled Trail. - Nil

开始日期2023-12-15

申办/合作机构

AiiMs Group

NCT01174979

/ Suspended临床3期

Double Blind, Placebo-controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Transtympanic Treatment of Tinnitus With Caroverine

This trial is a randomized, double blind, placebo controlled study on patients suffering from inner ear diseases with tinnitus as a principal symptom.
The study will investigate the transtympanic treatment with a 1,5 % caroverine solution.
Each patient will undergo treatment for 2 cycles of 48 hours each.

开始日期2011-01-01

申办/合作机构

Phafag AG

100 项与卡罗维林相关的临床结果

登录后查看更多信息

100 项与卡罗维林相关的转化医学

登录后查看更多信息

100 项与卡罗维林相关的专利（医药）

登录后查看更多信息

76

项与卡罗维林相关的文献（医药）

2024-11-01·Indian Journal of Pharmacology

Comparative analysis of efficacy, safety, and cost-effectiveness of betahistine alone, caroverine alone, and caroverine plus ginkgo biloba in moderate tinnitus

Article

作者: Rautray, Subhalaxmi ; Dehury, Suhasini ; Sahu, Debadutta ; Sahu, Lorika ; Nayak, Laxmipriya

Abstract:BACKGROUND:Tinnitus or “phantom sound” continues to be a significant health problem without a uniformly accepted treatment. Numerous pharmaceutical options have been investigated, but satisfactory results are yet to be obtained.OBJECTIVES:The objectives of this study were to study and compare the efficacy, safety, and cost-effectiveness of caroverine alone, caroverine combined with ginkgo biloba and betahistine alone in patients of moderate tinnitus.MATERIALS AND METHODS:In this prospective, observational, hospital-based study, wherein 72 patients were distributed equally across three groups – Group A received caroverine 20 mg twice daily, Group B received caroverine 20 mg combined with ginkgo biloba 120 mg twice daily, and Group C received betahistine 8 mg thrice daily for 12 weeks. Efficacy was zanalyzed assessing the changes in tinnitus handicap inventory (THI), tinnitus functional index (TFI), Visual Analog Scale (VAS) score, and pure tone audiometry values from baseline at 4, 8 and 12 weeks. The cost-effectiveness analysis was done at the end of 12 weeks zutilizing the incremental costeffectiveness ratio. The Chi-square test and one-way ANOVA were used to evaluate the statistical significance of the results.RESULTS:The reduction in the THI, TFI and VAS scores was maximum in Group B followed by Group A and Group C. All the drugs were well-tolerated, and the adverse effects encountered were mild and nonserious. Combination therapy of caroverine with gingkgo biloba was the most expensive.CONCLUSION:Caroverine and ginkgo biloba combination therapy was the most effective in reducing the handicap of moderate tinnitus.

2024-10-01·Journal of Family Medicine and Primary Care

Effect of oral caroverine in the treatment of tinnitus: A quasi-experimental study

Article

作者: Prusty, Nilamadhaba ; Barik, Prasanjit A. ; Bisoyi, Sasmita K. ; Panda, Abinash ; Satpathy, Manas R. ; Dash, Anil K.

ABSTRACTObjective:Caroverine is an antagonist of non-NMDA and NMDA glutamate receptors. Cochlear synaptic tinnitus arises from a synaptic disturbance of NMDA or non-NMDA receptors on the afferent dendrites of spiral ganglion neurons. This forms a basis for the use of caroverine in the treatment of tinnitus. Hence, the present study was carried out to find the effect of oral caroverine in the treatment of tinnitus.Methodology:This quasi-experimental study was carried out on sixty consecutive patients of tinnitus. Thirty patients were given the usual standard of care consisting of Tab. Cinnarizine 25mg twice daily along with fixed dose combination Cap. B-complex and Ginkgo biloba once daily for ninety days and thirty patients were given Cap. Caroverine 40mg, twice daily for ninety days. Outcome assessment was done using the tinnitus case history questionnaire, tinnitus handicap inventory score, and VAS. The data were analyzed using GraphPad Prism Trial Version. A P value ≤ 0.05 was taken as statistically significant.Results:There was a significant improvement in the tinnitus case history questionnaire score at 90 days in patients suffering from mild tinnitus when treated with caroverine. There was a larger decrease in the tinnitus handicap inventory score at 90 days of treatment in the caroverine-treated patients. The median VAS showed an improvement in the caroverine-treated group. The overall reduction in tinnitus in the caroverine-treated group was 53.3% with an odds ratio, 95% CI of 0.375 (0.12-1.08).Conclusion:Oral caroverine was found to be better than the usual standard of care in reducing mild cochlear synaptic tinnitus. It also improved sensory–neural hearing loss during the treatment period.

2024-10-01·Indian Journal of Otolaryngology and Head & Neck Surgery

A Comparative Analysis of the Efficacy of Ginkgo Biloba and Caroverine in the Management of Idiopathic Tinnitus

Article

作者: Saxena, Rohit ; Basista, Hitender ; Pathak, Vivek Kumar ; Awasthi, Sanjeev

AimThe sound sensation that is experienced in the ears or brain and is unrelated to any external sources of stimulus is known as tinnitus. Tinnitus Functional Index (TFI) is used to establish the presence of the condition and determine symptom severity, its impact on the patient's quality of life, thus in this study, we aim to compare the efficacy of caroverine and Ginkgo Biloba in the management of idiopathic tinnitus using TFI.MethodsThis clinical study was conducted in at a tertiary care hospital in North India, for a duration of one year, among patients with chronic tinnitus. The sample size for this study consisted of 60 patients in each of three groups (caroverine, gingko biloba, and multivitamin). Assessments of TFI and pure-tone audiometry were performed to evaluate the efficacy of the two medications. The information pertaining to the subjects was kept anonymous and confidential. During data analysis, an association was significant for p value < 0.05.ResultsThe patients in three groups were matched for the age, gender and duration of tinnitus. At 6 months of medication with Ginkgo Biloba, patients experienced a significant (p < 0.0001) decrease of 50.0% in tinnitus of moderate severity, and a complete resolution of severe tinnitus symptoms with a percentage change of -100.0%.ConclusionIn our study, Ginkgo Biloba Group has significantly improved the severity of idiopathic tinnitus. Tinnitus has diverse underlying mechanisms, can be a symptom of various underlying diseases, and is challenging to measure. Further research is warranted to validate and explore these treatment options further.

100 项与卡罗维林相关的药物交易

登录后查看更多信息